Eisai Inc v. Sanofi Aventis U.S. LLC

E-Law Admin/ Mai 4, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Eisai Inc v. Sanofi Aventis U.S. LLC, 14-2017

In an antitrust suit alleging the conduct of defendant harmed competition in the market for anticoagulant drugs by preventing hospitals from replacing Lovenox, one of defendant’s drugs with competing drugs, the District Court’s grant of summary judgment to defendant is affirmed where, analyzing plaintiff’s claims under the rule of reason, there is no evidence that defendant’s actions caused broad harm to the competitive nature of the anticoagulant market.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/05/04



  • United States Third Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar